Dosage Form Myths: What the Pharmacokinetic Data Shows

Dosage Form Myths: What the Pharmacokinetic Data Shows

▶ Watch the video

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Many headline bioavailability claims are more formulation-specific than advertised. A 2025 reappraisal found piperine's 2000 percent curcumin-bioavailability claim did not replicate; unconjugated plasma curcumin remained below the assay's quantification limit in most measurements, including the high-dose piperine condition. A 2025 scoping review of 10 liposomal-vitamin-C studies found 9 showed higher bioavailability, with AUC up to 7.2× that of non-liposomal. Buccal nanoemulsion vitamin D produced similar 25(OH)D improvement at half the conventional dose in one trial; a self-nanoemulsifying cannabinoid formulation raised THC but not CBD Cmax significantly. Absorption technology depends on molecule and formulation, not one multiplier. MIHIYO Labs sizes its oral dissolving strip (ODS) formulas to match each ingredient's pharmacology.

Do supplement absorption claims actually hold up to testing?

Some do, at least in part. The ones checked here often look smaller when tested in published human studies. When I read a claim like "2000% better absorption" or "next-generation nano-delivery," my first question as a pharmacist isn't whether the underlying chemistry is real — encapsulation, particle-size reduction, and mucosal delivery are all legitimate pharmaceutical tools. My question is narrower: did a published human study measure that number at a realistic dose, and who ran and paid for it? Often, when someone checks, the number shrinks — sometimes to nothing.

I formulate oral dissolving strips for a living, so I read absorption-enhancement literature constantly, for ingredients I use and ones I don't. Sublingual and buccal delivery is one technology people assume is automatically superior to swallowing. It isn't. It depends on the molecule. This article walks through four commonly marketed absorption claims — piperine-boosted curcumin, liposomal vitamin C, and nanoemulsion delivery for two different actives — against what the published human pharmacokinetic data actually measured.

Why absorption technology isn't a universal multiplier

Whether a delivery technology raises bioavailability depends on what's limiting that molecule's absorption in the first place — different molecules hit different limits. Oral bioavailability is the fraction of a dose that reaches systemic circulation unchanged. For a swallowed molecule, that can be capped by poor water solubility, extensive first-pass liver metabolism, or both. Liposomes and nanoemulsions often improve solubilization and intestinal uptake of poorly soluble compounds; depending on the formulation and molecule, lipid-based systems can also promote intestinal lymphatic uptake, which can partly route a drug around the portal-vein path that exposes it to first-pass liver metabolism8. They shouldn't be treated as purely solubility-only technologies, though how much lymphatic-transport benefit any given formulation achieves depends heavily on the molecule and lipid system used.

Sublingual and buccal delivery works on a different axis. Placing a molecule against oral mucosa can let some of it enter the bloodstream directly, partly bypassing first-pass metabolism — but only if the molecule can physically cross that tissue. Permeation across sublingual mucosa depends strongly on lipophilicity and ionization state: across the compounds tested, permeability increased with lipophilicity, and pH-dependent ionization mattered too, though not simply — permeability fell as pH rose for the tested compound, yet ionized species could still dominate flux above its pKa, since the contribution of each species depends on thermodynamic activity as well as ionization state1. A poorly lipophilic molecule that remains heavily ionized at oral pH is generally a poor candidate for passive transmucosal absorption unless the formulation specifically addresses the delivery barrier — for example, with a permeation enhancer, or with mucoadhesion to extend residence time when longer contact can improve uptake — and without that, it will still depend mostly on gut absorption after being swallowed. This is why one dosage form is not a blanket upgrade over another — the same choice can decide one ingredient's outcome and be irrelevant for the next.

That is also the design constraint I hold every MIHIYO formulation to: for mucosal delivery to contribute meaningfully, a strip needs sufficient residence time and drug release while it is in contact with the oral mucosa. If it is swallowed almost immediately — instead of letting it sit and dissolve — a larger share of the dose is likely to depend on gastrointestinal absorption instead, which is why dissolution time and matrix choice are formulation decisions, not just a mouthfeel preference.

Why oral mucosal absorption is not automatic for every molecule A lipophilic, un-ionized molecule can cross sublingual mucosa and partly bypass first-pass liver metabolism, while a poorly lipophilic, ionized molecule is blocked by the same mucosal barrier and still depends mainly on absorption in the gut. Lipophilic, un-ionized molecule Poorly lipophilic, ionized molecule Sublingual mucosa Lipid barrier, gated by pKa Sublingual mucosa Same barrier, same tissue Crosses into circulation Partial first-pass bypass Largely blocked Route unavailable for most of the dose Swallowed, digested Absorption depends on the gut route Lipophilicity and ionization state — not the dosage form alone — decide whether mucosal delivery changes absorption.

What the pharmacokinetic data actually shows

I compared four commonly marketed absorption-enhancement concepts against what published human data actually measured — noting, where it matters, who funded the study.

Claim Typical marketing framing What the cited data shows Source
Piperine + curcumin "2000% increase in bioavailability" No measurable AUC benefit at 2280 mg curcuminoids + 20 mg piperine; unconjugated plasma curcumin remained below 2 nM in most measurements Kroon et al., 20252
Liposomal vitamin C (single RCT) Claims of superior absorption AUC of 10.3 mg/dL·h vs. 7.6 mg/dL·h for unencapsulated oral vitamin C — about 1.35x, and below the intravenous arm Davis et al., 20163
Liposomal vitamin C (across studies) Same framing, applied broadly Scoping review of 10 studies, 9 of which showed higher bioavailability: Cmax 1.2–5.4× and AUC 1.3–7.2× that of non-liposomal vitamin C, with wide variability by formulation and dose Carr, 20254
Self-nanoemulsifying cannabinoid formulation (SNEDDS) Claims of next-generation absorption technology THC Cmax rose 3.2-fold (p = 0.044) vs. an oil-based formulation; CBD's 2.2-fold rise was not statistically significant (p = 0.121); subjective-effect difference faded by 4 hours Hermush et al., 20255
Buccal nanoemulsion vitamin D Claims of superior bioavailability Equivalent serum 25(OH)D increase at roughly half the daily dose of conventional oral cholecalciferol, in patients with inflammatory bowel disease Kojecký et al., 20256

The measured effects varied substantially by molecule and formulation. Liposomal vitamin C reached up to roughly 7.2-fold higher AUC across the review, while the CBD Cmax difference in the cannabinoid trial didn't reach statistical significance. At the other extreme, the widely cited 2000% piperine-curcumin claim didn't replicate in the 2025 reappraisal. Vitamin D and cannabinoid also aren't comparable to each other: vitamin D showed a 12–16-week serum 25(OH)D response at two different total doses — a dose-efficiency signal, not a matched-dose PK multiplier (more below) — while the cannabinoid trial measured Cmax directly but was funded by the formulation's maker. Molecule, dose, and funding source all matter as much as the delivery format itself.

Measured absorption gains from enhancement technology are modest, not the multiples often advertised Published pharmacokinetic data for piperine-boosted curcumin, liposomal vitamin C, and nanoemulsion cannabinoids show measured gains ranging from no effect to about seven-fold, well below the ten-fold to twenty-fold increases commonly advertised for these technologies. 1x no gain 0x 4x 8x Curcumin + piperine ~1.0x — no measurable AUC gain Liposomal vitamin C (single RCT, AUC) 1.35x Liposomal vitamin C (10-study range, AUC) up to 7.2x Nanoemulsion THC (Cmax, single crossover) 3.2x Marketing for these same technologies commonly cites 10x to 2000% higher absorption.

What this means for MIHIYO's formulations

I did not build liposomal or nanoemulsion versions of MIHIYO's actives, and the reasoning differs by ingredient, to avoid repeating this article's own mistake of lumping molecules together. Melatonin has real human evidence for transmucosal absorption: a 1997 crossover study in 12 men found that transmucosal (buccal) melatonin produced prompt systemic melatonin levels with less between-subject variability than oral controlled-release delivery9, consistent with partial first-pass bypass — part of the basis for the Sleep-Support strip's low-dose design. Caffeine is different: a 2025 randomized crossover trial found a sublingual caffeine spray did not raise blood caffeine faster than a caffeinated beverage at a matched 60 mg dose7. A spray is not a strip, so that result doesn't settle the question for MIHIYO's own format, but it's a direct reason not to assume mucosal contact alone speeds absorption. I formulate the Energy-Focus strip for rapid dissolution and possible early mucosal exposure, not as a claim that it delivers more total caffeine than a swallowed capsule — swallowed caffeine itself already has essentially complete oral bioavailability in a human oral-vs-IV pharmacokinetic study10, a distinction I cover in more depth in how fast caffeine strips actually work.

For 5-HTP and L-theanine in Mood-Boost, I have not found human pharmacokinetic studies that isolate and quantify buccal or sublingual absorption well enough to support a specific mucosal-delivery advantage, so I do not claim one — the strip format is chosen for water-free, precise dosing, not for a specific absorption-technology benefit. At the doses used across MIHIYO's three strips, none requires a liposomal or nanoemulsion system to reach a workable formulation — including melatonin, which is itself poorly water-soluble, unlike caffeine, 5-HTP, or L-theanine. I would rather formulate around what each molecule's own pharmacology actually supports than borrow a bioavailability claim from a study on an unrelated compound — that substitution is exactly the mistake the curcumin-piperine data above illustrates.

Where even validated absorption technology falls short

Even the claims that do hold up carry real limits, some with caveats about the studies themselves. The self-nanoemulsifying cannabinoid trial was funded by Capsoil Technologies Ltd., the maker of the tested formulation, and one author is its CEO — properly disclosed, with the CEO uninvolved in data collection, analysis, or writing, but still a reason to read the result as industry-sponsored, not fully independent. Nor was the design a clean formulation-vs-oil comparison: the powder was dissolved in water and swallowed, while the oil drops were held under the tongue for 1–2 minutes, so the Cmax difference partly reflects that dosing difference, not just the formulation; the crossover order was fixed rather than randomized, and only 14 people were enrolled.

The vitamin D trial, run in patients with inflammatory bowel disease, measured serum 25(OH)D response over 12–16 weeks rather than a direct Cmax/AUC comparison at a matched dose, and its own authors noted individual variability in the conventional-dose group that intestinal absorption differences alone did not fully explain — a genuinely useful result for that population, but not a general nanoemulsion-vs-capsule bioavailability multiplier. It says nothing about whether the same format would outperform a standard vitamin D capsule in someone with normal gut absorption.

A separate, easy-to-miss limitation is that a higher plasma number does not automatically mean a better outcome. In the Davis et al. liposomal vitamin C trial, all three vitamin C arms — unencapsulated oral, liposomal oral, and intravenous — protected equally well against ischemia-reperfusion oxidative stress, despite meaningfully different plasma concentrations between them. Absorption and effect are not the same measurement, and a formulation that wins on one does not automatically win on the other. And absence of a measured difference cuts the other way too: no detectable difference between two formulations in a small trial is not the same as proven equivalence — it can also mean the study wasn't large enough to find a real difference that exists.

The bottom line

The size of a bioavailability claim is an empirical question, not a marketing constant, and the claims examined here shrink substantially against published human data. Among comparisons that showed higher pharmacokinetic exposure, measured increases ranged from roughly 1.3-fold to 7.2-fold; other comparisons showed no measurable benefit or did not reach statistical significance. The vitamin D study instead showed a dose-efficiency signal rather than a matched-dose pharmacokinetic multiplier. Real gains depend on the specific molecule, formulation, dose, funding source, and sometimes the population being studied. MIHIYO Labs sizes each oral dissolving strip to what its own active ingredient's published pharmacology actually supports, rather than reaching for an absorption-technology claim that was measured on an unrelated compound.

Measured absorption gains are modest, not the multiples often advertised Video-trimmed version of the absorption-data chart, without the marketing-claim caption line, sized to fit the short-form video figure panel and stay clear of the presenter nameplate. 1x 0x 4x 8x Curcumin + piperine ~1.0x — no gain Liposomal vitamin C (single RCT) 1.35x Liposomal vitamin C (10-study review) 7.2x Nanoemulsion THC 3.2x

References

  1. Goswami T, Li X, Jasti BR. Effect of Lipophilicity and Drug Ionization on Permeation Across Porcine Sublingual Mucosa. AAPS PharmSciTech. 2017;18(1):175-181. PMID: 26931443 / DOI: 10.1208/s12249-016-0479-1. https://pubmed.ncbi.nlm.nih.gov/26931443/
  2. Kroon MAGM, van Laarhoven HWM, Swart EL, van Tellingen O, Kemper EM. A pharmacokinetic study and critical reappraisal of curcumin formulations enhancing bioavailability. iScience. 2025. PMID: 40487425 / DOI: 10.1016/j.isci.2025.112575. https://pmc.ncbi.nlm.nih.gov/articles/PMC12144411/
  3. Davis JL, Paris HL, Beals JW, Binns SE, Giordano GR, Scalzo RL, Schweder MM, Blair E, Bell C. Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury. Nutrition and Metabolic Insights. 2016;9:25-30. PMID: 27375360 / DOI: 10.4137/NMI.S39764. https://pubmed.ncbi.nlm.nih.gov/27375360/
  4. Carr AC. Do Liposomal Vitamin C Formulations Have Improved Bioavailability? A Scoping Review Identifying Future Research Directions. Basic & Clinical Pharmacology & Toxicology. 2025;137(1):e70067. PMID: 40506693 / DOI: 10.1111/bcpt.70067. https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70067
  5. Hermush V, Mizrahi N, Brodezky T, Ezra R. Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation. Journal of Cannabis Research. 2025. DOI: 10.1186/s42238-025-00294-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC12166629/
  6. Kojecký V, Klhůfek J, Kianička B, Kohout P. Improved bioavailability of buccal nanoemulsion vitamin D compared to conventional oral supplementation in patients with inflammatory bowel disease: a randomized controlled trial. Frontiers in Medicine. 2025. PMID: 40927197 / DOI: 10.3389/fmed.2025.1649677. https://pmc.ncbi.nlm.nih.gov/articles/PMC12414931/
  7. McCarthy DG, Stapleton RK, Handy RM, Amanual S, Tsioros S, Millar PJ, Burr JF. Sublingual caffeine delivery via oral spray does not accelerate blood caffeine increase compared to ingestion of caffeinated beverages. European Journal of Applied Physiology. 2025;125(7):2007-2013. PMID: 40000478 / DOI: 10.1007/s00421-025-05735-z. https://pubmed.ncbi.nlm.nih.gov/40000478/
  8. Ahn H, Park J-H. Liposomal delivery systems for intestinal lymphatic drug transport. Biomaterials Research. 2016;20:36. PMID: 27895934 / DOI: 10.1186/s40824-016-0083-1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5120490/
  9. Bénès L, Claustrat B, Horrière F, Geoffriau M, Konsil J, Parrott KA, DeGrande G, McQuinn RL, Ayres JW. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. Journal of Pharmaceutical Sciences. 1997;86(10):1115-1119. PMID: 9344167 / DOI: 10.1021/js970011z. https://pubmed.ncbi.nlm.nih.gov/9344167/
  10. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. European Journal of Clinical Pharmacology. 1983;24:93-98. PMID: 6832208 / DOI: 10.1007/BF00613933. https://pubmed.ncbi.nlm.nih.gov/6832208/

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.